세계의 세마글루티드(Semaglutide) 시장 : 규모, 점유율, 동향 분석(제품별, 용도별, 투여 경로별, 유통 채널별, 지역별), 부문별 예측(2025-2035년)
Semaglutide Market Size, Share & Trends Analysis Report By Product (Ozempic, Wegovy, Rybelsus), By Application (Type 2 Diabetes Mellitus, Obesity), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2035
상품코드
:
1726260
리서치사
:
Grand View Research, Inc.
발행일
:
2025년 04월
페이지 정보
:
영문 100 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세마글루티드 시장의 성장과 동향
Grand View Research, Inc.의 최신 보고서에 따르면 세계 세마글루티드 시장 규모는 2035년까지 936억 달러에 이르고, 예측 기간 동안 CAGR 10.47%로 성장할 것으로 예측됩니다.
세마글루티드 산업은 세계의 당뇨병과 비만의 유병률 증가에 견인되어 성장을 이루고 있습니다.
당뇨병 관리에서 글루카곤 유사 펩타이드-1 수용체 작용제(GLP-1 RA)에 대한 수요가 증가함에 따라 세마글루타이드가 주요 치료 옵션으로 자리 잡았습니다.
세마글루티드 시장의 주요 촉진요인으로는 2형 당뇨병과 비만의 부담 증가를 들 수 있으며, 효과적인 치료 개입에 대한 수요가 높아지고 있습니다. 심혈관 위험을 줄이고 체중 관리를 돕는 약물의 효능 덕분에 당뇨병 치료를 넘어 사용이 확대되었습니다.또한, 유리한 상환 정책이나 자기 투여 주사 요법의 채용 확대도 시장 성장에 기여하고 있습니다.
의료 인프라 투자 증가와 당뇨병 관리에 대한 의식이 높아짐에 따라 시장은 신흥 경제권에서 확대될 가능성이 있습니다. 세마글루타이드가 체중 감량에 효과가 있는 것으로 입증되어 여러 지역에서 규제 승인을 받았기 때문에 비만 치료 분야에서 추가적인 시장 침투 가능성도 있습니다.
세마글루티드 업계는 높은 연구 개발 투자, 엄격한 규제 감독, 강력한 지적 재산 보호를 특징으로 합니다.
세마글루티드는 제형, 제조 방법 및 치료 용도를 다루는 여러 특허로 보호됩니다. 자동차 시장 독점권을 지속적으로 확보하고 있습니다. 경구제나 서방형 제제 등의 대체 제제에 투자하고 있는 기업은 당초의 유효기간을 넘어 상업적인 이용 가능성을 확대하기 위해, 추후 특허 보호를 요구하고 있습니다.
최근 시장 사례로는 비만 치료 등의 새로운 치료 영역에서 세마글루티드가 승인되어 그 상업적 가능성이 대폭 확대된 것을 들 수 있습니다.
세마글루티드 업계는 당뇨병과 비만의 유병률 증가, 약물 전달의 기술 진보, 지속적인 연구개발 이니셔티브에 힘입어 지속적인 성장을 이루는 태세에 있습니다. 특허 보호는 단기적인 시장 독점을 보장하지만, 대체 제형과 병용 요법이 등장함에 따라 경쟁 역학이 변화할 수 있습니다.
세마글루티드 시장 : 분석 개요
- 제품 유형별로는 오젠픽이 2024년 매출액 점유율 59.62%로 시장을 석권했습니다. 강력한 임상 효과, 폭넓은 규제 당국의 승인, 2형 당뇨병에의 채택 증가의 결과입니다.
- 용도별로는 2형 당뇨병이 시장을 석권해, 2024년의 매출액 점유율은 71.16%였습니다.
- 투여 경로별로는 비경구 투여 경로가 시장을 석권해 2024년에는 88.46%의 점유율을 차지했습니다.
- 판매 채널별로는 소매 약국이 시장을 리드해, 2024년에는 55.09%의 점유율을 차지했습니다.
- 주요 시장 진출 기업은 Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, 그리고 AstraZeneca등 입니다.
- 2025년 3월, Novo Nordisk의 3b상 STRIDE시험은 오젠픽(세마글루티드 1.0mg)이 2형 당뇨병과 PAD를 가진 성인 환자의 보행거리를 13% 개선한다는 것을 보여주었습니다.
목차
제1장 분석 방법 및 범위
제2장 주요 요약
제3장 세마글루티드 시장 : 변동 요인, 경향, 범위
- 시장 연관 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비즈니스 환경 분석
- 업계 분석 - Porter's Five Forces 분석
- PESTLE 분석
- 파이프라인 분석 :상별
- 특허 만료 분석
- 가격 분석
- 경쟁 구도 : 특허 취득 후 세마 글루 티드 시장의 신흥 바이오 시밀러
제4장 세마글루티드 시장 : 제품별 비즈니스 분석
- 시장 점유율 : 제품별(2024년 및 2035년)
- 제품별 대시보드
- 시장 규모 예측과 동향 분석 : 제품별(2018-2035년)
- Ozempic
- Wegovy
- Rybelsus
- 기타
제5장 세마글루티드 시장 : 용도별 비즈니스 분석
- 시장 점유율 : 용도별(2024년 및 2035년)
- 용도별 대시보드
- 시장 규모 예측과 동향 분석 : 용도별(2018-2035년)
- 2형 당뇨병
- 비만
- 기타
제6장 세마글루티드 시장 : 투여 경로별 비즈니스 분석
- 시장 점유율 : 투여 경로별(2024년 및 2035년)
- 투여 경로별 대시보드
- 시장 규모 예측과 동향 분석 : 투여경로별(2018-2035년)
- 비경구
- 경구
제7장 세마글루티드 시장 : 유통 채널별 비즈니스 분석
- 시장 점유율 : 유통 채널별(2024년 및 2035년)
- 유통 채널별 대시보드
- 시장 규모 예측과 동향 분석 : 유통채널별(2018-2035년)
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세마글루티드 시장 : 지역별 비즈니스 분석
- 시장 점유율 : 지역별(2024년 및 2035년)
- 지역별 대시보드
- 시장 규모 예측과 동향 분석 : 지역별(2018-2035년)
- 북미
- 국가별(2018-2035년)
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제9장 경쟁 구도
- 참가 기업 개요
- 기업 시장 포지션 분석
- 기업 분류
- 전략 매핑
- 기업 프로파일, 상장 기업
- Novo Nordisk A/S
- Eli Lilly
- Viking Therapeutics
- Lexicon Pharmaceuticals
- Biocon
- AstraZeneca
SHW
영문 목차
Semaglutide Market Growth & Trends:
The global semaglutide market size is anticipated to reach USD 93.60 billion by 2035, growing at a CAGR of 10.47% during the forecast period, according to a new report by Grand View Research, Inc. The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments.
The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial potential.
The market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market reach.
The semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded indications.
Semaglutide is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration dates.
Recent market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation formulations.
The semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market landscape.
Semaglutide Market Report Highlights:
- Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes.
- Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
- Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations.
- Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy.
- Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires.
- In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Semaglutide Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis, by Phase
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.6. Competitive Landscape: Emerging Biosimilars in the Post-Patent Semaglutide Market
Chapter 4. Semaglutide Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2035
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)
- 4.4. Ozempic
- 4.4.1. Ozempic Market, 2018 - 2035 (USD Million)
- 4.5. Wegovy
- 4.5.1. Wegovy Market, 2018 - 2035 (USD Million)
- 4.6. Rybelsus
- 4.6.1. Rybelsus Market, 2018 - 2035 (USD Million)
- 4.7. Others
- 4.7.1. Other Product Market, 2018 - 2035 (USD Million)
Chapter 5. Semaglutide Market: Application Business Analysis
- 5.1. Application Market Share, 2024 & 2035
- 5.2. Application Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)
- 5.4. Type 2 Diabetes Mellitus
- 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2035 (USD Million)
- 5.5. Obesity
- 5.5.1. Obesity Market, 2018 - 2035 (USD Million)
- 5.6. Others
- 5.6.1. Others Market, 2018 - 2035 (USD Million)
Chapter 6. Semaglutide Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2024 & 2035
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)
- 6.4. Parenteral
- 6.4.1. Parenteral Market, 2018 - 2035 (USD Million)
- 6.5. Oral
- 6.5.1. Oral Market, 2018 - 2035 (USD Million)
Chapter 7. Semaglutide Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2024 & 2035
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2018 - 2035 (USD Million)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2018 - 2035 (USD Million)
- 7.6. Online Pharmacies
- 7.6.1. Online Pharmacies Market, 2018 - 2035 (USD Million)
Chapter 8. Semaglutide Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2024 & 2035
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2035:
- 8.4. North America
- 8.4.1. North America Semaglutide Market Estimates And Forecasts, By Country, 2018 - 2035 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5. Europe
- 8.5.1. Europe Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. Uk Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. Novo Nordisk A/S
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Eli Lilly
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Viking Therapeutics
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Lexicon Pharmaceuticals
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Biocon
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. AstraZeneca
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
관련자료
